| scholarly article | Q13442814 |
| P50 | author | Ralf Michael Zwacka | Q57250345 |
| P2093 | author name string | Linda Howard | |
| Frank Barry | |||
| Tim O'Brien | |||
| Georgina Shaw | |||
| Mark Lyons | |||
| Andrea Mohr | |||
| Laura Deedigan | |||
| Ralf Zwacka | |||
| Tina Harte | |||
| P2860 | cites work | Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery | Q21147047 |
| Characterization of two receptors for TRAIL | Q24309064 | ||
| Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer | Q28211178 | ||
| Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors | Q28245164 | ||
| Human mesenchymal stem cells modulate allogeneic immune cell responses | Q28288692 | ||
| A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry | Q29617253 | ||
| Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli | Q29618769 | ||
| Immune responses to adenovirus and adeno-associated virus in humans. | Q33874473 | ||
| Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo | Q34040679 | ||
| Apoptosis in human glioblastoma cells produced using embryonic stem cell-derived astrocytes expressing tumor necrosis factor-related apoptosis-inducing ligand | Q34551591 | ||
| Current strategies and future directions for eluding adenoviral vector immunity | Q34585554 | ||
| Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. | Q34632614 | ||
| Intravascular adenoviral agents in cancer patients: lessons from clinical trials | Q35043094 | ||
| Mesenchymal stem cells: clinical applications and biological characterization. | Q35686355 | ||
| Alteration of marrow cell gene expression, protein production, and engraftment into lung by lung-derived microvesicles: a novel mechanism for phenotype modulation. | Q36035053 | ||
| Good manufacturing practice production of adenoviral vectors for clinical trials | Q36090101 | ||
| Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles | Q36901346 | ||
| Characterization and functionality of cell surface molecules on human mesenchymal stem cells | Q38357443 | ||
| Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs | Q40253468 | ||
| Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. | Q40297306 | ||
| Vascular endothelial growth factor A contributes to glioma-induced migration of human marrow stromal cells (hMSC). | Q40298054 | ||
| Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses | Q40302572 | ||
| AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression. | Q40582634 | ||
| Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene | Q40648897 | ||
| Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line. | Q40705843 | ||
| Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis | Q40860890 | ||
| Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. | Q43583253 | ||
| Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. | Q43696432 | ||
| Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation | Q44317237 | ||
| Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination | Q45758816 | ||
| Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity | Q45857523 | ||
| Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector | Q45863127 | ||
| Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration | Q45863202 | ||
| Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors | Q45869203 | ||
| Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. | Q45880303 | ||
| Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas | Q48926056 | ||
| Gene transfer into rat mesenchymal stem cells: a comparative study of viral and nonviral vectors. | Q50737303 | ||
| Migration of Bone Marrow and Cord Blood Mesenchymal Stem Cells In Vitro Is Regulated by Stromal-Derived Factor-1-CXCR4 and Hepatocyte Growth Factor-c-met Axes and Involves Matrix Metalloproteinases | Q57375767 | ||
| Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects | Q57384572 | ||
| Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect | Q64377565 | ||
| P433 | issue | 6B | |
| P921 | main subject | mesenchymal stem cell | Q1922379 |
| lung cancer | Q47912 | ||
| P304 | page(s) | 2628-2643 | |
| P577 | publication date | 2008-03-28 | |
| P1433 | published in | Journal of Cellular and Molecular Medicine | Q1524063 |
| P1476 | title | Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model | |
| P478 | volume | 12 |
| Q30986055 | A therapeutic strategy for choroidal neovascularization based on recruitment of mesenchymal stem cells to the sites of lesions |
| Q33613433 | AAV-iRFP labelling of human mesenchymal stem cells for near-infrared fluorescence imaging |
| Q47561992 | Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer |
| Q34135233 | Advances in mesenchymal stem cell-mediated gene therapy for cancer. |
| Q52608756 | Application of Mesenchymal Stem Cells for Therapeutic Agent Delivery in Anti-tumor Treatment. |
| Q47384260 | Caspase-10: a molecular switch from cell-autonomous apoptosis to communal cell death in response to chemotherapeutic drug treatment |
| Q37772453 | Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy? |
| Q55312940 | Construction and characterization of a new TRAIL soluble form, active at picomolar concentrations. |
| Q38108819 | Cytotherapies in multiple myeloma: a complementary approach to current treatments? |
| Q36215003 | DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer |
| Q49559607 | Delivery of Exogenous miR-124 to Glioblastoma Multiform Cells by Wharton's Jelly Mesenchymal Stem Cells Decreases Cell Proliferation and Migration, and Confers Chemosensitivity. |
| Q37073589 | Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects |
| Q42586818 | Effect of human Wharton's jelly mesenchymal stem cell secretome on proliferation, apoptosis and drug resistance of lung cancer cells |
| Q30420262 | Efficient lentiviral transduction of adipose tissue-derived mouse mesenchymal stem cells and assessment of their penetration in female mice cervical tumor model |
| Q64987315 | Engineered human mesenchymal stem cells for neuroblastoma therapeutics. |
| Q33604781 | Establishment and Characterization of a Nude Mouse Model of Subcutaneously Implanted Tumors and Abdominal Metastasis in Gastric Cancer |
| Q39840843 | Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence. |
| Q39003413 | Human mesenchymal stem cells with adenovirus-mediated TRAIL gene transduction have antitumor effects on esophageal cancer cell line Eca-109. |
| Q37211843 | Inhibition of hepatocellular carcinoma growth by adenovirus-mediated expression of human telomerase reverse transcriptase COOH-27 terminal polypeptide in mice |
| Q37185756 | Interferon-β gene-modified human bone marrow mesenchymal stem cells attenuate hepatocellular carcinoma through inhibiting AKT/FOXO3a pathway |
| Q64244641 | MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma |
| Q90196428 | MSC.sTRAIL Has Better Efficacy than MSC.FL-TRAIL and in Combination with AKTi Blocks Pro-Metastatic Cytokine Production in Prostate Cancer Cells |
| Q57174410 | Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour |
| Q38938230 | Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas |
| Q34710895 | Mesenchymal stem cell-based NK4 gene therapy in nude mice bearing gastric cancer xenografts |
| Q37390890 | Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. |
| Q35159519 | Mesenchymal stem cells expressing interleukin-18 suppress breast cancer cells in vitro |
| Q36661456 | Mesenchymal stem cells increase proliferation but do not change quiescent state of osteosarcoma cells: Potential implications according to the tumor resection status |
| Q39377126 | Mesenchymal stem cells modified to express interferon-β inhibit the growth of prostate cancer in a mouse model |
| Q37294534 | Mesenchymal stem cells modified to express lentivirus TNF-α Tumstatin(45-132) inhibit the growth of prostate cancer |
| Q39432344 | Mesenchymal stem cells: A new platform for targeting suicide genes in cancer. |
| Q38885494 | Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy. |
| Q33729242 | NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL |
| Q37049935 | Redox-Active Mn Porphyrin-based Potent SOD Mimic, MnTnBuOE-2-PyP(5+), Enhances Carbenoxolone-Mediated TRAIL-Induced Apoptosis in Glioblastoma Multiforme. |
| Q38750240 | TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models |
| Q35681794 | TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill. |
| Q36312145 | The inhibitory effect of MSCs expressing TRAIL as a cellular delivery vehicle in combination with cisplatin on hepatocellular carcinoma |
| Q37211949 | The mesenchymal stromal cell contribution to homeostasis |
| Q39323223 | Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma |
| Q36887716 | Therapeutic strategies targeting cancer stem cells |
| Q34164696 | Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging |
| Q37948053 | Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers |